The international NeoSep1 has begun recruiting newborns in India. The first infant was enrolled at JIPMER, followed by a baby at Pt. B.D. Sharma PGIMS, Rohtak, and soon at a hospital in Mumbai. The trial is part of a global effort led by the GARDP Foundation, in collaboration with UK universities and the Penta Foundation.
Key Developments
- First Indian enrolment at JIPMER on 2026.
- Subsequent enrolments at Pt. B.D. Sharma PGIMS, Rohtak and planned recruitment in Mumbai.
- Goal to enrol 3,000 newborns across Asia and Africa by the end of 2028.
- Trial uses a PRACTical approach to rank antibiotic regimens.
- Part 1 (2023) validated doses of fosfomycin and flomoxef in South Africa and Kenya.
Important Facts
Neonatal sepsis is a bloodstream infection in babies younger than 90 days. It is classified as early‑onset (first 72 hours) or late‑onset (up to 28–90 days). In India, sepsis accounts for 30‑40 % of neonatal deaths, translating to roughly 2‑2.5 lakh preventable deaths annually. The dominant pathogens are gram‑negative organisms, unlike high‑income countries where Group B Streptococcus is common.
The trial’s primary outcome is death within 28 days; secondary outcomes include death within 90 days, need for additional antibiotics, length of hospital stay and readmission.
Exam Relevance
Understanding the NeoSep1 trial helps aspirants link three important UPSC themes:
- Public health policy: Shows how India participates in global research to tackle antimicrobial resistance.
- Health infrastructure: Highlights the role of premier institutions like JIPMER in conducting high‑impact clinical trials.
- Research methodology: Introduces the PRACTical design, relevant for questions on evidence‑based policy making.
Way Forward
For policymakers, the trial underscores the need to:
- Strengthen laboratory capacity for rapid pathogen identification.
- Promote affordable, locally‑effective antibiotic regimens identified by the study.
- Integrate trial findings into national neonatal care guidelines.
- Support collaborative research platforms that address region‑specific disease patterns.
Successful outcomes could reduce the massive burden of drug‑resistant neonatal sepsis and help India meet its Sustainable Development Goal target for child health.